SG11201707345VA - Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection - Google Patents
Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infectionInfo
- Publication number
- SG11201707345VA SG11201707345VA SG11201707345VA SG11201707345VA SG11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA
- Authority
- SG
- Singapore
- Prior art keywords
- agent
- lysosomotropic
- treatment
- combination
- bacterial infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15158880 | 2015-03-12 | ||
PCT/EP2016/055076 WO2016142445A2 (en) | 2015-03-12 | 2016-03-10 | A method of treatment of a bacterial infection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707345VA true SG11201707345VA (en) | 2017-10-30 |
Family
ID=52648929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201707345VA SG11201707345VA (en) | 2015-03-12 | 2016-03-10 | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
Country Status (12)
Country | Link |
---|---|
US (1) | US11690899B2 (en) |
EP (1) | EP3268023B1 (en) |
JP (1) | JP2018509415A (en) |
KR (1) | KR20170132201A (en) |
CN (1) | CN107580503B (en) |
AU (1) | AU2016231141B2 (en) |
BR (1) | BR112017019413A2 (en) |
CA (1) | CA2979873A1 (en) |
HK (1) | HK1249033A1 (en) |
IL (1) | IL254457B (en) |
SG (1) | SG11201707345VA (en) |
WO (1) | WO2016142445A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017360064C1 (en) * | 2016-11-18 | 2022-04-07 | Lysando Ag | New antimicrobial agents against staphylococcus aureus |
EP3692149B1 (en) | 2017-10-06 | 2023-01-04 | Micreos Human Health B.V. | Treatment of a condition associated with infection with an oncogenic bacterium |
US11266743B2 (en) | 2017-10-25 | 2022-03-08 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods of use thereof |
US11149068B2 (en) | 2018-01-05 | 2021-10-19 | The Administrator Of The Tulane Educational Fund | Pore-forming peptides and uses thereof |
JP7131803B2 (en) * | 2018-05-15 | 2022-09-06 | 学校法人大阪医科薬科大学 | Preventive or therapeutic agent for diseases caused by Gb3 accumulation |
CN109350618B (en) * | 2018-12-10 | 2021-09-28 | 山东农业大学 | Application of autophagy regulator in elimination of staphylococcus aureus in bovine mammary epithelial cells |
GB201906653D0 (en) * | 2019-05-10 | 2019-06-26 | Cc Biotech Ltd | Polypeptides for treatment of bacterial infections |
IL296529A (en) | 2020-03-19 | 2022-11-01 | Micreos Human Health Bv | A stabilized protein of interest |
WO2024020533A1 (en) * | 2022-07-22 | 2024-01-25 | Endolytix Technology, Inc. | Immunogenic compositions for treating or preventing actinomycetia infections |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020187136A1 (en) * | 2000-04-28 | 2002-12-12 | Lawrence Loomis | Use of bacterial phage associated lysing enzymes for treating various illnesses |
US20040023897A1 (en) * | 2001-11-13 | 2004-02-05 | Caplan Michael J. | Methods for preventing or treating disease mediated by toxin-secreting bacteria |
KR100759988B1 (en) * | 2006-08-04 | 2007-09-19 | 주식회사 인트론바이오테크놀로지 | Antimicrobial protein specific to staphylococcus aureus |
US20100028334A1 (en) * | 2006-12-15 | 2010-02-04 | Trustees Of Boston University | Compositions and methods to potentiate colistin activity |
US8383102B2 (en) | 2009-05-21 | 2013-02-26 | The United States Of America As Represented By The Secretary Of Agriculture | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens |
KR20120059576A (en) | 2009-08-24 | 2012-06-08 | 뤼산도 홀딩 아게 | New endolysin obpgplys |
EP2338916A1 (en) | 2009-12-23 | 2011-06-29 | Hyglos Invest GmbH | Chimeric polypeptides and their use in bacterial decoloniation |
WO2012146738A1 (en) | 2011-04-27 | 2012-11-01 | Lysando Holding Ag | New antimicrobial agents |
PL3085777T3 (en) * | 2011-05-04 | 2020-05-18 | Micreos Human Health B.V. | A polypeptide |
JP2015522533A (en) * | 2012-05-07 | 2015-08-06 | マイクレオス ヒューマン ヘルス ビー.ブイ.Micreos Human Health B.V. | Polypeptide mix with antibacterial activity |
KR20230113404A (en) * | 2012-05-09 | 2023-07-28 | 콘트라펙트 코포레이션 | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
US9603909B2 (en) * | 2012-05-29 | 2017-03-28 | Intron Biotechnology, Inc. | Composition capable of improving stability of bacteriophage lysin proteins |
US9206411B2 (en) * | 2012-06-13 | 2015-12-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus |
EP2679677A1 (en) | 2012-06-29 | 2014-01-01 | Lysando Aktiengesellschaft | Composition for use in Mycobacteria therapy |
US20160097044A1 (en) | 2014-10-01 | 2016-04-07 | The United States Of America, As Represented By The Secretary Of Agriculture | Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus |
-
2016
- 2016-03-10 CN CN201680026953.2A patent/CN107580503B/en active Active
- 2016-03-10 BR BR112017019413A patent/BR112017019413A2/en active Search and Examination
- 2016-03-10 US US15/557,296 patent/US11690899B2/en active Active
- 2016-03-10 KR KR1020177028879A patent/KR20170132201A/en active IP Right Grant
- 2016-03-10 CA CA2979873A patent/CA2979873A1/en active Pending
- 2016-03-10 SG SG11201707345VA patent/SG11201707345VA/en unknown
- 2016-03-10 JP JP2017547980A patent/JP2018509415A/en active Pending
- 2016-03-10 WO PCT/EP2016/055076 patent/WO2016142445A2/en active Application Filing
- 2016-03-10 EP EP16709389.7A patent/EP3268023B1/en active Active
- 2016-03-10 AU AU2016231141A patent/AU2016231141B2/en active Active
-
2017
- 2017-09-12 IL IL254457A patent/IL254457B/en active IP Right Grant
-
2018
- 2018-07-06 HK HK18108776.3A patent/HK1249033A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20180271952A1 (en) | 2018-09-27 |
AU2016231141B2 (en) | 2022-03-03 |
WO2016142445A2 (en) | 2016-09-15 |
EP3268023B1 (en) | 2021-08-18 |
CN107580503A (en) | 2018-01-12 |
KR20170132201A (en) | 2017-12-01 |
JP2018509415A (en) | 2018-04-05 |
WO2016142445A3 (en) | 2016-11-10 |
BR112017019413A2 (en) | 2018-05-02 |
IL254457B (en) | 2020-03-31 |
IL254457A0 (en) | 2017-11-30 |
HK1249033A1 (en) | 2018-10-26 |
AU2016231141A1 (en) | 2017-09-28 |
CN107580503B (en) | 2021-07-09 |
CA2979873A1 (en) | 2016-09-15 |
EP3268023A2 (en) | 2018-01-17 |
US11690899B2 (en) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250639A1 (en) | Antimicrobial therapy | |
HK1249033A1 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
ZA201802719B (en) | Treatment compositions providing an antimicrobial benefit | |
IL270695B1 (en) | Catheter | |
HRP20190580T1 (en) | Combination therapy for treatment of resistant bacterial infections | |
HK1255105A1 (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
SG11201606247QA (en) | Antimicrobial inserts for medical devices | |
EP3263152A4 (en) | Medical treatment device | |
CA186425S (en) | Catheter | |
PL3448992T3 (en) | Antimicrobial agents against salmonella bacteria | |
SG11202001205PA (en) | Anti-occlusion catheter | |
GB201813876D0 (en) | Treatment | |
ZA201801134B (en) | Hydroxytriazine compound and medical use thereof | |
GB201800546D0 (en) | Treatment | |
PL3497095T3 (en) | Zinc chelating compounds for use in the treatment of bacterial infection | |
SG11201808307QA (en) | Multi-diameter cannula | |
IL253878A0 (en) | Respiratory infection treating agent | |
CA186424S (en) | Catheter | |
GB201807050D0 (en) | Medical uses | |
GB2558090B (en) | Prevention and treatment for microbial infections | |
GB201708650D0 (en) | Combination therapy for bacterial infection | |
GB201814905D0 (en) | Treatment | |
GB201711677D0 (en) | Combination treatment | |
GB201704949D0 (en) | Combination treatment | |
GB201704303D0 (en) | Catheter |